{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T06:07:55Z","timestamp":1779084475423,"version":"3.51.4"},"reference-count":19,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T00:00:00Z","timestamp":1779062400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pediatr."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Children with Down syndrome (DS) show a higher incidence of acute lymphoblastic leukemia (ALL) compared to general population. They are almost entirely affected by B-cell precursor ALL, linked to the constitutional chromosome 21 trisomy and associated with recurrent mutational patterns. The occurrence of T-cell ALL (T-ALL) is extremely rare in DS patients, with only few reports described. This entity remains poorly characterized either genetically and clinically, and there are no standardized guidelines for the treatment of these rare and fragile patients. Here we describe the case of a child with DS and T-ALL and provide comprehensive genetic characterization of his disease.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case report<\/jats:title>\n                    <jats:p>\n                      A previously well 7-year-old boy with DS was diagnosed with T-ALL presenting with leukocytosis, mediastinal mass and central nervous system involvement (CNS2). Genetic studies showed a complex karyotype with the translocation t(1;14)(p32;q11) and deletion of chromosome 9p. RNA sequencing was negative for fusion transcript. Next-generation sequencing analysis for somatic mutations on DNA material showed pathogenic variants in\n                      <jats:italic>NOTCH1<\/jats:italic>\n                      and\n                      <jats:italic>FBXW7<\/jats:italic>\n                      . Chemotherapy was started according to AIEOP-BFM ALL 2017 study. During induction phase, the patient suffered from multiple severe complications, requiring significant treatment modifications and an anthracycline-free induction. However, the patient presented favorable response achieving minimal residual disease negativity. He is currently on maintenance therapy 15 months from the diagnosis.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This case provides the first detailed genetic characterization of T-ALL in a child with DS. The findings of typical T-ALL somatic mutations and genetic alterations suggest a sporadic leukemogenesis origin, distinct from the specific pathway associated with B-cell precursor ALL. We confirm the rarity of this entity and the extreme susceptibility to treatment complications. An improved knowledge and characterization of DS T-ALL might be helpful to inform clinicians about treatment decision making for this very rare disease.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fped.2026.1820038","type":"journal-article","created":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T05:43:52Z","timestamp":1779083032000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["The very rare association between T-cell acute lymphoblastic leukemia and down syndrome: a case report and review of the literature"],"prefix":"10.3389","volume":"14","author":[{"given":"Giacomo","family":"Gotti","sequence":"first","affiliation":[{"name":"Pediatrics, Fondazione IRCCS San Gerardo dei Tintori","place":["Monza, Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura Rachele","family":"Bettini","sequence":"additional","affiliation":[{"name":"Pediatrics, Fondazione IRCCS San Gerardo dei Tintori","place":["Monza, Italy"]},{"name":"School of Medicine and Surgery, University Milano-Bicocca","place":["Monza, Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefano","family":"Rebellato","sequence":"additional","affiliation":[{"name":"Tettamanti Center, Fondazione IRCCS San Gerardo dei Tintori","place":["Monza, Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valentino","family":"Conter","sequence":"additional","affiliation":[{"name":"Tettamanti Center, Fondazione IRCCS San Gerardo dei Tintori","place":["Monza, Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonella","family":"Colombini","sequence":"additional","affiliation":[{"name":"Pediatrics, Fondazione IRCCS San Gerardo dei Tintori","place":["Monza, Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Veronica","family":"Leoni","sequence":"additional","affiliation":[{"name":"Pediatrics, Fondazione IRCCS San Gerardo dei Tintori","place":["Monza, Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandra","family":"Sala","sequence":"additional","affiliation":[{"name":"Pediatrics, Fondazione IRCCS San Gerardo dei Tintori","place":["Monza, Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Spinelli","sequence":"additional","affiliation":[{"name":"Pediatrics, Fondazione IRCCS San Gerardo dei Tintori","place":["Monza, Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Biondi","sequence":"additional","affiliation":[{"name":"Tettamanti Center, Fondazione IRCCS San Gerardo dei Tintori","place":["Monza, Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Grazia","family":"Fazio","sequence":"additional","affiliation":[{"name":"School of Medicine and Surgery, University Milano-Bicocca","place":["Monza, Italy"]},{"name":"Tettamanti Center, Fondazione IRCCS San Gerardo dei Tintori","place":["Monza, Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adriana Cristina","family":"Balduzzi","sequence":"additional","affiliation":[{"name":"Pediatrics, Fondazione IRCCS San Gerardo dei Tintori","place":["Monza, Italy"]},{"name":"School of Medicine and Surgery, University Milano-Bicocca","place":["Monza, Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmelo","family":"Rizzari","sequence":"additional","affiliation":[{"name":"Pediatrics, Fondazione IRCCS San Gerardo dei Tintori","place":["Monza, Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/S0140-6736(99)05264-2","article-title":"Risks of leukaemia and solid tumours in individuals with down\u2019s syndrome","volume":"355","author":"Hasle","year":"2000","journal-title":"Lancet"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1182\/blood.2018890764","article-title":"Inherited genetic susceptibility to acute lymphoblastic leukemia in down syndrome","volume":"134","author":"Brown","year":"2019","journal-title":"Blood"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1182\/blood-2009-08-235408","article-title":"Down syndrome acute lymphoblastic leukemia, a highly heterogeneous disease in which aberrant expression of CRLF2 is associated with mutated JAK2: a report from the international BFM study group","volume":"115","author":"Hertzberg","year":"2010","journal-title":"Blood"},{"key":"B4","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1182\/blood-2013-06-509463","article-title":"Acute lymphoblastic leukemia in children with down syndrome: a retrospective analysis from the ponte di legno study group","volume":"123","author":"Buitenkamp","year":"2014","journal-title":"Blood"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1200\/JCO.1993.11.7.1361","article-title":"Immunophenotypes and karyotypes of leukemic cells in children with down syndrome and acute lymphoblastic leukemia","volume":"11","author":"Pui","year":"1993","journal-title":"J Clin Oncol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"e27256","DOI":"10.1002\/pbc.27256","article-title":"Outcome of children and adolescents with down syndrome treated on Dana-farber cancer institute acute lymphoblastic leukemia consortium protocols 00\u2013001 and 05\u2013001","volume":"65","author":"Athale","year":"2018","journal-title":"Pediatr Blood Cancer"},{"key":"B7","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1002\/cncr.23587","article-title":"Acute lymphoblastic leukemia and down syndrome","volume":"113","author":"Arico","year":"2008","journal-title":"Cancer"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1038\/s41586-024-07807-0","article-title":"The genomic basis of childhood T-lineage acute lymphoblastic leukaemia","volume":"632","author":"P\u00f6l\u00f6nen","year":"2024","journal-title":"Nature"},{"key":"B9","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1038\/s41408-022-00683-9","article-title":"Potential role of STAG1 mutations in genetic predisposition to childhood hematological malignancies","volume":"12","author":"Saitta","year":"2022","journal-title":"Blood Cancer J"},{"key":"B10","doi-asserted-by":"publisher","first-page":"2077","DOI":"10.1182\/blood-2011-03-338707","article-title":"Late MRD response determines relapse risk overall and in subsets of childhood T-cell ALL: results of the AIEOP-BFM-ALL 2000 study","volume":"118","author":"Schrappe","year":"2011","journal-title":"Blood"},{"key":"B11","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1182\/blood-2013-07-453480","article-title":"How I treat ALL in down\u2019s syndrome: pathobiology and management","volume":"123","author":"Izraeli","year":"2014","journal-title":"Blood"},{"key":"B12","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1200\/JCO.23.00389","article-title":"Outcomes in children, adolescents, and young adults with down syndrome and ALL: a report from the children\u2019s oncology group","volume":"42","author":"Rabin","year":"2024","journal-title":"J Clin Oncol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"2926","DOI":"10.1200\/JCO.2018.77.7250","article-title":"Improved survival for children and young adults with T-lineage acute lymphoblastic leukemia: results from the children\u2019s oncology group AALL0434 methotrexate randomization","volume":"36","author":"Winter","year":"2018","journal-title":"J Clin Oncol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1182\/bloodadvances.2023010303","article-title":"Nelarabine: when and how to use in the treatment of T-cell acute lymphoblastic leukemia","volume":"8","author":"Shimony","year":"2024","journal-title":"Blood Adv"},{"key":"B15","doi-asserted-by":"publisher","first-page":"3282","DOI":"10.1200\/JCO.20.00256","article-title":"Children\u2019s oncology group AALL0434: a phase III randomized clinical trial testing nelarabine in newly diagnosed T-cell acute lymphoblastic leukemia","volume":"38","author":"Dunsmore","year":"2020","journal-title":"J Clin Oncol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1158\/2159-8290.CD-14-0353","article-title":"Maturation stage of T-cell acute lymphoblastic leukemia determines BCL-2 versus BCL-XL dependence and sensitivity to ABT-199","volume":"4","author":"Chonghaile","year":"2014","journal-title":"Cancer Discov"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1158\/2159-8290.CD-20-1465","article-title":"Venetoclax and navitoclax in combination with chemotherapy in patients with relapsed or refractory acute lymphoblastic leukemia and lymphoblastic lymphoma","volume":"11","author":"Pullarkat","year":"2021","journal-title":"Cancer Discov"},{"key":"B18","doi-asserted-by":"publisher","first-page":"e350","DOI":"10.1038\/bcj.2015.80","article-title":"A phase 1 study of the novel gamma-secretase inhibitor PF-03084014 in patients with T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma","volume":"5","author":"Papayannidis","year":"2015","journal-title":"Blood Cancer J"},{"key":"B19","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1172\/JCI62372","article-title":"DYRK1A In down syndrome: an oncogene or tumor suppressor?","volume":"122","author":"Birger","year":"2012","journal-title":"J Clin Invest"}],"container-title":["Frontiers in Pediatrics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2026.1820038\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T05:43:53Z","timestamp":1779083033000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2026.1820038\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,18]]},"references-count":19,"alternative-id":["10.3389\/fped.2026.1820038"],"URL":"https:\/\/doi.org\/10.3389\/fped.2026.1820038","relation":{},"ISSN":["2296-2360"],"issn-type":[{"value":"2296-2360","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,18]]},"article-number":"1820038"}}